AstraZeneca PLC (LON:AZN)

London flag London · Delayed Price · Currency is GBP · Price in GBX
10,484
+48 (0.46%)
May 27, 2025, 5:15 PM BST
-14.74%
Market Cap 161.82B
Revenue (ttm) 42.56B
Net Income (ttm) 6.02B
Shares Out 1.55B
EPS (ttm) 3.85
PE Ratio 27.13
Forward PE 15.13
Dividend 2.36 (2.26%)
Ex-Dividend Date Feb 20, 2025
Volume 1,135,289
Average Volume 2,410,362
Open 10,490
Previous Close 10,436
Day's Range 10,464 - 10,598
52-Week Range 9,574 - 13,388
Beta 0.18
RSI 51.77
Earnings Date Apr 29, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]

Sector Healthcare
Founded 1992
Employees 94,300
Stock Exchange London Stock Exchange
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD Financial Statements

News

Aptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening Algorithms

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health and AstraZeneca announce licensing agreement to develop AI-powered screening algorithms for early disease detection.

5 days ago - Business Wire

AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer

SERENA-6 plenary presentation will feature next-generation oral SERD camizestrant in 1st-line advanced HR-positive breast cancer MATTERHORN plenary presentation will showcase perioperative treatment w...

6 days ago - Benzinga

AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American S...

6 days ago - Business Wire

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the BATURA Phase IIIb trial showed AstraZeneca's anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated ...

8 days ago - Business Wire

Market shake-up: Tech edges up while energy and consumer stocks drag

Sector Overview The US stock market today exhibits a diversified portfolio of trends, as revealed by the latest heatmap snapshot. Technology stands out marginally in the green, while energy and major ...

8 days ago - Forexlive

35 Barron's Pro-Picks: One Ideal May DiviDog

Barron's interviewed eleven financial industry Roundtable-pros who tapped 65 predictions. Six non-ADR foreign-stocks and four mutual funds were dropped by YCharts screens of active US listings, leavin...

9 days ago - Seeking Alpha

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers

Study also met secondary endpoint of overall survival (OS) for patients whose tumors express PD-L1 KEYTRUDA ® (pembrolizumab) plus chemotherapy (paclitaxel) with or without bevacizumab is the first im...

12 days ago - Benzinga

P/E Ratio Insights for AstraZeneca

In the current session, AstraZeneca Inc. (NASDAQ: AZN) is trading at $66.27, after a 2.14% drop. Over the past month, the stock decreased by 1.16% , and in the past year, by 13.98% . With performance...

13 days ago - Benzinga

BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma

Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical respo...

13 days ago - Accesswire

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoraci...

14 days ago - Business Wire

AstraZeneca and GSK in the firing line as Trump targets big pharma: ALEX BRUMMER

No one expected US peace in our time at the Geneva talks with China at the weekend, but what emerged is better than predicted.

14 days ago - This is Money

Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices

Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.

15 days ago - CNBC Television

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.

15 days ago - WSJ

Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'

President plans to use executive powers, saying US should pay ‘same price as nation that pays the lowest price'

15 days ago - The Guardian

AstraZeneca (AZN) Faces Market Uncertainty Amid Drug Pricing Changes | AZN Stock News

AstraZeneca (AZN) Faces Market Uncertainty Amid Drug Pricing Changes | AZN Stock News

15 days ago - GuruFocus

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG inductio...

18 days ago - Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer Positive ...

20 days ago - Benzinga

Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model

Tempus AI Inc. (NASDAQ: TEM) during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” What Happened: During its first-quarter earning...

20 days ago - Benzinga

ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

Daiichi Sankyo and AstraZeneca's ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results ...

20 days ago - Benzinga